HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?
Nat Clin Pract Gastroenterol Hepatol
.
2005 Dec;2(12):568-9.
doi: 10.1038/ncpgasthep0337.
Author
Andrew J Muir
1
Affiliation
1
Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27710, USA.
[email protected]
PMID:
16327834
DOI:
10.1038/ncpgasthep0337
No abstract available
Publication types
Comment